Corrigendum to “Herceptin-Mediated Cardiotoxicity: Assessment by Cardiovascular Magnetic Resonance”
First published: 23 July 2025
J. Jiang, B. Liu, and S. Hothi, “Herceptin-Mediated Cardiotoxicity: Assessment by Cardiovascular Magnetic Resonance,” Cardiology Research and Practice (2022), https://doi.org/10.1155/2022/1910841.
In the article, the authors have identified errors in Table 5. The correct Table 5 is shown as follows:
| T1 | T2 | EGE | LGE | ECV | ↓ LVEF | ↑ LV volume | ↓ RVEF | Cardiotoxicity/cardiac dysfunction | |
|---|---|---|---|---|---|---|---|---|---|
| Herceptin | ✓ (89) | ✓ [69, 81, 82] X (90) | ✓ (50) | ✓ (73) | ✓ (50) | 2%–27%∗ (49) | |||
| Anthracycline (doxorubicin) | ✓ (87) | ✓ (87, 91) | ✓ (87) | X (90) | ✓ (92, 93) | ✓ (91) | ✓ (70, 94) | ✓ (70) | 3%–26% (53, 54) |
| Pertuzumab | ✓ (56) | 6.6% (95) | |||||||
| Lapatinib | ✓ (57, 65) | 2.7% (96) | |||||||
| Epirubicin | ✓ (97) | ✓ (97) | ✓ (98) | ✓ (99) | 0.7%–11.4% (100) |
- Note: T1, T1 mapping; T2, T2 mapping; ECV, extracellular volume; ↓ LVEF, reduction in left ventricular ejection fraction; ↓ RVEF, reduction in right ventricular ejection fraction.
- Abbreviations: EGE, early gadolinium enhancement; LGE, late gadolinium enhancement; LV, left ventricular.
- ∗The patient cohort in these trials may have been pre-exposed to anthracycline.
We apologize for this error.
